Altimmune (ALT) Accumulated Expenses (2010 - 2026)

Altimmune (ALT) has 17 years of Accumulated Expenses data on file, last reported at $9.8 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $9.8 million, up 875.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.8 million (up 875.4% YoY), and the FY2025 annual result was $4.7 million, down 27.43% from the prior year.
• Accumulated Expenses improved to $9.8 million in Q1 2026 per ALT's latest filing, from $4.7 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $12.5 million in Q2 2024 and troughed at $48000.0 in Q3 2022.
• A 5-year average of $5.3 million and a median of $4.7 million in 2025 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2024: Accumulated Expenses plunged 99.75% in 2022, then soared 20337.7% in 2024.
• A 5-year view of Accumulated Expenses shows it stood at $12.2 million in 2022, then tumbled by 72.94% to $3.3 million in 2023, then jumped by 94.36% to $6.4 million in 2024, then decreased by 27.43% to $4.7 million in 2025, then soared by 109.43% to $9.8 million in 2026.
• Business Quant data shows ALT's Accumulated Expenses at $9.8 million in Q1 2026, $4.7 million in Q4 2025, and $4.6 million in Q3 2025.